Tubulis

Acquired

Tubulis is a biotech company in Munich, Germany, founded in 2019. It has raised $578.4M across 3 rounds, most recently a $359.2M Series C in October 2025.

Next-generation antibody-drug conjugates for durable cancer treatment

Headquarters
Munich, Bavaria
Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$578.4M
Last Round
$359.2M Series COct 2025
Rounds
3
Acquisition Date
May 2026

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 15 investors for this company. The full record is or through the API.

About

Tubulis is a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for the treatment of solid and hematologic tumors. Founded in 2019 in Munich, Germany by Dr. Dominik Schumacher and Dr. Jonas Helma-Smets — both formerly group leaders at Ludwig Maximillian University — the company developed a proprietary ADC platform designed to generate uniquely matched conjugates with superior biophysical properties, delivering durable on-tumor activity and long-lasting anti-tumor effects in preclinical models. Tubulis' lead pipeline programs include TUB-040 (targeting NaPi2b) and TUB-030 (directed against 5T4), both in clinical evaluation for high-need solid tumor indications. The company raised over €308M in its Series C financing round in October 2025 to advance TUB-040 into Phase I/IIa trials. In April 2026, Gilead Sciences announced an agreement to acquire Tubulis in a deal worth up to $5 billion.

Summary

It lists 51–200 employees. It has raised $578.4M in total across 3 rounds, most recently a $359.2M Series C round in Oct 2025. Investors include Andera Partners, Gilead Sciences and Venrock.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionMay 2026

Sign up to see all 4 events

Funding: Series B through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tubulis on Indexed.vc
<a href="https://indexed.vc/companies/tubulis"><img src="https://indexed.vc/api/badge/company/tubulis" alt="Tubulis on Indexed.vc" width="260" height="76" /></a>